BRCA2 and prostate carcinoma: Future in vivo experiments in mouse models will assess the therapeutic potential of 6-TG in the treatment of BRCA2-deficient prostate cancers, and of 2-N-6-BP- and 2,6-DTP in the treatment of BRCA2-proficient, advanced prostate cancers.